Aclarion Yönetim

Yönetim kriter kontrolleri 4/4

Aclarion CEO'su Brent Ness, Sep2021 tarihinde atandı, in görev süresi 3.17 yıldır. in toplam yıllık tazminatı $ 300.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.013% ine doğrudan sahiptir ve bu hisseler $ 237.06 değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 3.2 yıldır.

Anahtar bilgiler

Brent Ness

İcra Kurulu Başkanı

US$300.0k

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	3.2yrs
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	3.1yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Brent Ness'un ücretlendirmesi Aclarion'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	-US$6m
Dec 31 2023	US$300k	US$300k	-US$5m
Sep 30 2023	n/a	n/a	-US$5m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$7m
Dec 31 2022	US$509k	US$300k	-US$7m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$526k	US$100k	-US$6m

Tazminat ve Piyasa: Brent 'nin toplam tazminatı ($USD 300.00K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 653.78K ).

Tazminat ve Kazançlar: Brent 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Brent Ness (57 yo)

3.2yrs

Görev süresi

US$300,000

Tazminat

Mr. Brent Ness has been President of Aclarion, Inc. (fka Nocimed, Inc.) since October 1, 2021 and its Chief Executive Officer & Director since September 15, 2021. From December 2019 to April 2021, Mr. Ness...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeffrey Thramann	Executive Chairman	4.2yrs	US$300.00k	0% $ 0
Brent Ness	CEO, President & Director	3.2yrs	US$300.00k	0.013% $ 237.1
John Lorbiecki	Chief Financial Officer	3.1yrs	US$225.00k	0.014% $ 259.2
Ryan Bond	Chief Strategy Officer	3.2yrs	US$200.00k	0.012% $ 231.3

3.1yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: ACON 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeffrey Thramann	Executive Chairman	4.2yrs	US$300.00k	0% $ 0
Brent Ness	CEO, President & Director	3.2yrs	US$300.00k	0.013% $ 237.1
William Wesemann	Lead Independent Director	8.8yrs	US$40.00k	0.033% $ 610.0
Jeffrey Lotz	Member of Scientific Advisory Board	no data	US$12.86k	Veri yok
Stephen Deitsch	Independent Director	2.6yrs	US$45.00k	0% $ 0
Scott Breidbart	Independent Director	2.6yrs	US$40.00k	0% $ 0
Robert Eastlack	Member of Medical Advisory Board	no data	US$14.77k	Veri yok
David Neal	Director	8.2yrs	US$25.00k	0.12% $ 2.2k
Amanda Williams	Independent Director	2.6yrs	US$35.00k	0% $ 0
Lawrence Tannenbaum	Member of Medical Advisory Board	no data	US$10.40k	Veri yok

3.2yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ACON 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Aclarion Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

High number of new and inexperienced directors

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Recent updates

Aclarion Provides Update on Non-Compliance with Nasdaq’s Stockholders’ Equity Requirement and Nasdaq’s Bid Price Requirement

Aclarion, Inc. announced that it has received $1 million in funding

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Aclarion, Inc. has filed a Follow-on Equity Offering in the amount of $1.075 million.

Aclarion Launches Surgeon Partnership to Apply Nociscan's Ai Technology to Personal Injury and Workers Compensation Market

Aclarion Receives Non-Compliance Letter from Nasdaq Due to Non-Compliance with the Nasdaq Minimum Stockholders’ Equity Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.44 loss per share (vs US$2.39 loss in 1Q 2023)

Aclarion Receives Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Aclarion, Inc. has completed a Composite Units Offering in the amount of $3.0015 million.

Full year 2023 earnings released: US$8.82 loss per share (vs US$19.61 loss in FY 2022)

Aclarion Announces Updated Product Release That Expands Mri Scanner Access for Nociscan Solution

New major risk - Shareholder dilution

Aclarion, Inc. announced that it has received $0.25 million in funding

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.21 loss in 3Q 2022)

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Aclarion, Inc., Annual General Meeting, Dec 18, 2023

Nasdaq Staff Determines to Delist the Aclarion Common Stock from Nasdaq, Unless the Company Timely Requests an Appeal of the Staff’s Determination to A Hearings Panel

Nasdaq Confirms Aclarion Regains Compliance with Rule 5250(c)(1) Regarding Filing of 10-Q Report

Aclarion Announces Update on Non-Compliance Notice from Nasdaq Regarding Late Filing of 10-Q Report

High number of new and inexperienced directors

Aclarion Receives Non-Compliance Notice From Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq

Aclarion, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aclarion, Inc. Receives Nasdaq Notice Regarding Late Filing of 10-Q Report

Aclarion, Inc. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.25 loss per share (vs US$6.58 loss in FY 2021)

Aclarion, Inc. George Frey MD as Key Opinion Leader

Aclarion, Inc. Receives a Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Aclarion, Inc’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD

High number of new directors

Aclarion, Inc.'s Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back Pain

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings released: US$1.35 loss per share (vs US$0.81 loss in 1Q 2021)

Director recently bought US$150k worth of stock

High number of new directors

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

Aclarion, Inc. has completed an IPO in the amount of $9.41775 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş